li001

Researcher Develops Nanotherapy to Break Barriers in Glioblastoma Treatment

Treatment /

Researchers have developed an experimental nanotherapy aimed at overcoming two major challenges in treating glioblastoma: the blood-brain barrier and drug resistance. The approach uses tiny lipid particles called liposomes to carry two existing drugs—everolimus (or rapamycin) and vinorelbine—directly to tumor cells. By delivering both drugs together, the therapy blocks tumor growth pathways and prevents cancer […]

Researcher Develops Nanotherapy to Break Barriers in Glioblastoma Treatment Read More »

Emactuzumab Shows Strong Phase 3 Results, Offering Short-Course Treatment Option for TGCT

Treatment /

The Phase 3 TANGENT trial showed that emactuzumab significantly improves outcomes for patients with tenosynovial giant cell tumor compared to placebo. At six months, patients receiving the drug had higher tumor response rates and greater reductions in tumor size. Many also experienced quick and lasting improvements in physical function, including less pain, better movement, and

Emactuzumab Shows Strong Phase 3 Results, Offering Short-Course Treatment Option for TGCT Read More »

Off-the-Shelf CAR T Therapy Cema-Cel Shows Strong Early Results in Lymphoma Trial

Clinical Trails /

Interim results from the phase 2 ALPHA3 trial suggest that cema-cel, an off-the-shelf CAR T-cell therapy, may significantly improve outcomes for patients with large B-cell lymphoma who remain MRD-positive after initial treatment. In this high-risk group, the therapy achieved MRD negativity in 58.3% of patients, compared to just 16.7% with standard observation. Circulating tumor DNA

Off-the-Shelf CAR T Therapy Cema-Cel Shows Strong Early Results in Lymphoma Trial Read More »

SRRM1 Identified as Key Driver of Chemotherapy Resistance in Pancreatic Cancer, Opening Door to New Combination Therapy

Research Advances /

Researchers have identified a key gene, SRRM1, that helps pancreatic cancer cells resist gemcitabine, the standard first-line chemotherapy. Higher levels of SRRM1 are linked to more advanced disease, metastasis, and poorer survival outcomes. When SRRM1 is blocked in resistant cancer cells, they become sensitive again to gemcitabine, suggesting it plays a central role in treatment

SRRM1 Identified as Key Driver of Chemotherapy Resistance in Pancreatic Cancer, Opening Door to New Combination Therapy Read More »

mRNA Cancer Vaccine Shows Long-Term Immune Protection and Delays Pancreatic Cancer Recurrence

Research Advances /

A long-term follow-up study of an individualized mRNA neoantigen vaccine for pancreatic cancer shows sustained immune activity and strong links to improved survival after surgery. Patients whose immune systems responded to the vaccine had not yet reached median recurrence-free survival after more than three years, while non-responders relapsed in about 13.4 months. The results suggest

mRNA Cancer Vaccine Shows Long-Term Immune Protection and Delays Pancreatic Cancer Recurrence Read More »

TREM2 Identified as Protective Immune Regulator in Pancreatic Cancer, Offering New Treatment Insights

Research Advances /

Researchers have identified a surprising role for the immune receptor TREM2 in pancreatic cancer, where it appears to protect against tumor growth rather than promote it. In pancreatic ductal adenocarcinoma, higher levels of TREM2 are linked to more stable immune activity, while low TREM2 is associated with aggressive, inflammatory tumors. Using advanced single-cell analysis, scientists

TREM2 Identified as Protective Immune Regulator in Pancreatic Cancer, Offering New Treatment Insights Read More »

Pancreatic Cancer Research Advances Focus on Early Detection, Immune Resistance, and Personalized Treatment

Research Advances /

Pancreatic cancer remains one of the deadliest cancers, with only about a 13% five-year survival rate. The main challenges are late diagnosis and strong resistance to treatment. Researchers are improving early detection by combining traditional markers like CA 19-9 with new methods such as microRNAs, DNA methylation, and liquid biopsy tests that analyze tumor DNA

Pancreatic Cancer Research Advances Focus on Early Detection, Immune Resistance, and Personalized Treatment Read More »

Dual-Target CAR T Therapy Shows Strong Results in Older Multiple Myeloma Patients

Clinical Trails /

A phase 1 trial shows that a dual-target CAR T-cell therapy called AZD0120 is highly effective and safe for older adults with newly diagnosed multiple myeloma, including frail patients. The study included patients with a median age of 72 and found extremely strong early results. All patients achieved a complete response and no detectable cancer

Dual-Target CAR T Therapy Shows Strong Results in Older Multiple Myeloma Patients Read More »

CAR T-Cell Therapy Shows Promise for Treating Autoimmune Diseases

Targeted Therapy /

Researchers are adapting CAR T-cell therapy, originally developed for cancer treatment, to treat autoimmune diseases such as lupus, multiple sclerosis (MS), and rheumatoid arthritis. The approach works by collecting a patient’s T cells and genetically modifying them to target and destroy overactive B cells, which are responsible for mistakenly attacking healthy tissues in autoimmune conditions.

CAR T-Cell Therapy Shows Promise for Treating Autoimmune Diseases Read More »

Daraxonrasib Extends Survival in Advanced Pancreatic Cancer in Phase 3 Trial

Treatment /

The phase 3 RASolute 302 trial shows that daraxonrasib (RMC-6236) significantly improves survival in patients with previously treated metastatic pancreatic cancer compared with standard chemotherapy. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy, representing a 60% reduction in the risk of death. The drug also improved

Daraxonrasib Extends Survival in Advanced Pancreatic Cancer in Phase 3 Trial Read More »